research Evolution of Ritlecitinib Population Pharmacokinetic Models During Clinical Drug Development
Ritlecitinib shows promise as a versatile treatment for various autoimmune and inflammatory diseases.
Search
for
Sort by
Research
960-990 / 1000+ results research Efficacy and Safety of Topical Adenosine for Androgenetic Alopecia in Adults: A Systematic Review
Topical adenosine may effectively and safely treat hair loss.
research Hair Loss Is a Potential Side Effect of Novel Oral Anticoagulants – Findings From the Dresden Noac Registry (NCT01588119)
Hair loss can be a side effect of certain blood thinners.
research NIPAL4 mutation c.527C˃A identified in Romanian patients with autosomal recessive congenital ichthyosis
The NIPAL4 mutation c.527C>A is common in Romanian patients with autosomal recessive congenital ichthyosis.
research Finasteride Tablets
research Finasteride Tablets
research PSS20 MEDIATION MODELING AND MEASUREMENT CHARACTERISTICS OF THE ITCH SEVERITY SCORE FROM A PHASE 2B TRIAL OF ORAL CP-690-550 IN PATIENTS WITH MODERATE TO-SEVERE PLAQUE PSORIASIS
CP-690,550 significantly reduced itching in patients with moderate-to-severe plaque psoriasis.
research Isotretinoin
Isotretinoin is a preferred treatment for severe acne, often leading to long-term improvement, but requires careful monitoring due to potential side effects.
research America - A Diversity of Life Styles.
The drug showed promise in treating renal cell carcinoma with manageable side effects.
research Severe Refractory Scarring Alopecia Associated With Combinational Use of Ficlatuzumab (AV-299) and Gefitinib
Combining Ficlatuzumab and Gefitinib can cause severe hair loss.
research A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
The study conducted a cost-per-responder analysis comparing ritlecitinib and baricitinib for treating severe alopecia areata. Ritlecitinib, a JAK3/TEC inhibitor, showed greater efficacy and a lower cost per responder than baricitinib, a JAK1/2 inhibitor, at both Weeks 24 and 52. Specifically, 52.10% of ritlecitinib initiators achieved a significant response by Week 24 compared to 36.28% for baricitinib. By Week 52, 40.26% of ritlecitinib users reached the desired outcome versus 30.63% for baricitinib. The cost per responder was lower for ritlecitinib at both time points, suggesting it may be a more cost-effective option for inclusion in treatment plans for severe alopecia areata.
research Treatment of actinic cheilitis with ingenol mebutate gel: Experience in four patients
Finasteride for hair loss in young men increases the risk of sexual dysfunction.
research Efficacy and Safety of Topical 5% Azelaic Acid Solution Versus 2% Minoxidil Solution in the Treatment of Female Pattern Hair Loss
5% Azelaic acid is as effective as 2% Minoxidil for female pattern hair loss and could be an alternative for those allergic to Minoxidil or pregnant.
research Squalene-Containing Nanostructured Lipid Carriers Promote Percutaneous Absorption and Hair Follicle Targeting of Diphencyprone for Treating Alopecia Areata
Squalene-based carriers improve delivery of a treatment to hair follicles for alopecia areata.
research Alopecia areata and ritlecitinib: Unravelling response trajectories
Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.
research Selective delivery of adapalene to the human hair follicle under finite dose conditions using polymeric micelle nanocarriers
Polymeric micelle nanocarriers deliver adapalene more effectively to hair follicles than commercial products.
research Concomitant management of alopecia universalis and ulcerative colitis with upadacitinib
Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
research Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
Baricitinib significantly regrows hair in teens with severe alopecia areata.
research Pediatric Clinical Trial Program in Progress: A Phase 3 Study and Long-term Extension Study to Evaluate the Efficacy and Safety of Ritlecitinib in Children 6 to <12 years of Age With Severe Alopecia Areata
Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
research 414 A fitst-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and fluorescence contrast in skin cancer
BLZ-100 is safe for use in skin cancer surgery and may help identify cancerous tissue.
![Activity of 17β-(N-Alkyl/Arylformamido) and 17β-[(N-Alkyl/Aryl) Alkyl/Arylamido]-4-Methyl-4-Aza-5α-Androstan-3-Ones as 5α-Reductase Inhibitors in the Hamster Flank Organ and Ear](/images/research/861159f1-7bd4-420c-a16b-4829458efe68/small/15592.jpg)
research Activity of 17β-(N-Alkyl/arylformamido) and 17β-[(N-Alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-5α-androstan-3-ones as 5α-Reductase Inhibitors in the Hamster Flank Organ and Ear11The research has been supported by Endorecherche that is seeking patent protection for the new compounds. F. Labrie is President of Endorecherche.
The compounds tested could potentially treat hair loss and alopecia.
research DRUG NEWS
The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
research Chemical Mechanism of the Covalent Modification of 5.alpha.-Reductases by Finasteride as Probed by Secondary Tritium Isotope Effects
Finasteride modifies 5-alpha-reductases through a two-step process, affecting inhibitor potency and possibly causing side effects.
research Synthesis and structure–activity studies of side-chain derivatized arylhydantoins for investigation as androgen receptor radioligands
The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.
research Real-world assessment of ritlecitinib in patients with severe alopecia areata: a 24-week multicentre retrospective study
Ritlecitinib may be more effective for severe alopecia areata than conventional treatments.
research Formulation and Evaluation of Diclofenac Diethylamine Gel Using Natural Mucilages
Hibiscus mucilage is an effective gelling agent for diclofenac diethylamine gel.
research The physiological and pharmacological roles of prostaglandins in hair growth
Targeting the PGD2-DP2 pathway may help treat hair loss.
research Synthesis and bioactivity of new Finasteride conjugate
New Finasteride conjugate improves prostate treatment and vital signs in rats.
research Ingestion of minoxidil associated with elevated transaminases in the absence of ischemic hepatitis
Minoxidil ingestion can raise liver enzyme levels.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.